What is the order of aggressiveness of pancreatic cancers?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Pancreatic cancers can be ranked from most to least aggressive as follows: Pancreatic ductal adenocarcinoma (PDAC) is generally the most aggressive type, followed by acinar cell carcinoma, poorly differentiated pancreatic neuroendocrine tumors (PNETs), well-differentiated PNETs, solid pseudopapillary neoplasms, mucinous cystic neoplasms, and serous cystadenomas being the least aggressive. The aggressiveness of pancreatic cancer is determined by factors including cell differentiation, location within the pancreas, stage at diagnosis, and molecular characteristics 1.

Key Factors Influencing Aggressiveness

  • Cell differentiation: Well-differentiated tumors tend to have a better prognosis than poorly differentiated ones 1.
  • Location within the pancreas: Tumors located in the head of the pancreas may have a worse prognosis due to earlier involvement of major vessels and surrounding structures.
  • Stage at diagnosis: Early detection significantly impacts treatment outcomes, but pancreatic cancer is often diagnosed at advanced stages due to vague initial symptoms 1.
  • Molecular characteristics: Certain molecular markers, such as Ki-67 index, can help predict the aggressiveness of pancreatic neuroendocrine tumors 1.

Ranking of Pancreatic Cancers by Aggressiveness

  • Pancreatic ductal adenocarcinoma (PDAC): Most aggressive, with a 5-year survival rate of less than 10% 1.
  • Acinar cell carcinoma: Highly aggressive, with a slightly better prognosis than PDAC.
  • Poorly differentiated pancreatic neuroendocrine tumors (PNETs): Aggressive, with a worse prognosis than well-differentiated PNETs 1.
  • Well-differentiated PNETs: Less aggressive, with a better prognosis than poorly differentiated PNETs 1.
  • Solid pseudopapillary neoplasms: Low-grade malignancies with good prognosis.
  • Mucinous cystic neoplasms: Malignant potential, but less aggressive when detected early.
  • Serous cystadenomas: Typically benign and the least aggressive. It is essential to note that the ranking of pancreatic cancers by aggressiveness can vary depending on individual patient factors and the specific characteristics of the tumor 1.

From the Research

Pancreatic Cancers in Order of Aggressiveness

The following list outlines pancreatic cancers in order of aggressiveness, from most aggressive to least aggressive, based on available evidence:

  • Adenosquamous carcinomas: These are recently recognized under the "basal" like category in profiling studies and are actually even worse prognostically than PDACs 2
  • Pancreatic ductal adenocarcinoma (PDAC): This is the most common and most important cancer of the pancreas, with rapid mortality and poor five-year survival rates of 2%-9% 2, 3, 4
  • Poorly differentiated (neuro)endocrine carcinoma: This type of tumor is high grade and has a poor prognosis 5
  • Medullary carcinomas: These appear to have different biology and are more aggressive than some other types of pancreatic cancer 2
  • Acinar cell carcinomas: These are non-ductal cancers with their respective clinicopathologic and molecular associations 2
  • Ampullary adenocarcinoma: This type of cancer has a variable prognosis based on factors such as patient age, TNM classification, differentiation grade, and treatment modality received 6
  • Colloid carcinoma: This type of cancer has a much better behavior than PDAC and may require an entirely different treatment approach 2
  • Well differentiated (neuro)endocrine carcinoma: This type of tumor is low grade and has a better prognosis than poorly differentiated (neuro)endocrine carcinoma 5
  • Neuroendocrine tumors of the ampulla: These are distinct entities presenting clinically with jaundice and have a good outcome with pancreaticoduodenectomy 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.